<DOC>
	<DOCNO>NCT00985530</DOCNO>
	<brief_summary>Subjects acute promyelocytic leukemia ( APL ) come back ( relapse ) initial treatment go away initial therapy . This research study involve test investigational drug call Tamibarotene combination standard treatment relapse APL call arsenic trioxide . Tamibarotene approve Japan treat patient relapse APL since April 2005 . Tamibarotene family drug all-trans retinoic acid ( ATRA ) , medication subject receive previously treatment . ATRA tamibarotene cause APL cell differentiate ( become ) normal non-leukemia cell . Laboratory study tamibarotene show effective APL . The purpose study determine tamibarotene combination arsenic trioxide safe effective .</brief_summary>
	<brief_title>Tamibarotene Arsenic Trioxide Relapsed Acute Promyelocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>Must diagnosis relapse APL Must complete prior cancer treatment least 6 month prior study Must prior treatment include ATRA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>